(24/7 MARKET NEWS) – AVROBIO, Inc. (NASDAQ: AVRO) announced, this morning, that it agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash, to be paid in full at closing.
AVROBIO is trading at $1.28, up $0.505 (+65.14%), on 3.91M premarket shares traded.
Its 52-week range is $0.56 to $1.93. It’s blown through all of its recent resistance and, if its trading volume increases, it has a pathway to new 52-week highs.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
